New biomarker technology shows promising results for predicting the prognosis of patients with prostate cancer after radical prostatectomy. According to new research published in Cancers, the use of ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...

Metastatic castration-resistant prostate cancer (CRPC) is the lethal form of the disease. Many groups have performed mutational or immunohistochemistry (IHC) testing in metastatic CRPC to identify ...

Digital imaging technology has advanced as far as to allow automated scoring of immunohistochemistry (IHC) assays, often better than a pathologist could score visually. This is significant, given that ...

Immunohistochemistry uses antibodies to test tissue samples for specific types of antigens. It can often provide very specific results regarding cancer types or other diseases, helping doctors decide ...

A means of determining whether the loss of the tumor suppressor gene PTEN predicts lethal outcomes in patients has been determined by a team from the Dana-Farber Cancer Institute. Using quantitative ...